Rheumatoid arthritis is a systemic autoimmune rheumatic disorder of unknown etiology.
It is the most common form of inflammatory arthritis.
Patient usually complains of joint pain and/or swelling with morning stiffness that lasts for more than an hour.
Goals of treatment are clinical & radiological remission of disease and to reduce functional limitations & permanent joint damage.
Bone erosions occur commonly in elderly-onset rheumatoid arthritis (EORA), and clinical remission at 1 or 2 years does not appear to protect against the loss of bone in anticitrullinated protein antibody (ACPA)-positive EORA patients, according to a study.
New drug applications approved by US FDA as of 16 - 31 October 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Despite an increased risk of cardiovascular disease (CVD) and diabetes, compliance with diabetes screening guideline in rheumatoid arthritis (RA) remains suboptimal, with little difference compared to the general population, according to a recent study.
Rheumatoid arthritis remission may be sustained following abatacept tapering, particularly in patients with shorter disease duration and long sustained remission, according to a study. Furthermore, ultrasound is a useful tool to identify disease activity flare.
Treatment with tumour necrosis factor inhibitor (TNFi) does not carry a heightened risk of cancer recurrence in patients with rheumatoid arthritis (RA) and a history of cancer, as shown in a recent study.
Biologics therapy can be successfully tapered in most rheumatoid arthritis patients who have achieved sustained remission, especially in subgroups of male patients, those with exposure to a maximum of one previous biological disease-modifying antirheumatic drug, and those with low baseline inflammation or damage score, according to 2-year data from a recent study.
Using a multimodal intervention may improve uptake of influenza vaccination in patients with rheumatoid arthritis (RA), reports a study, adding that some subgroups may need a more potent approach for equivalent efficacy.
Tuberculosis (TB) is an important adverse event associated with the use of biologics, especially antitumour necrosis factor, in the management of autoimmune inflammatory rheumatic diseases, according to a study. Prophylaxis can effectively reduce the risk in patients testing positive for latent TB at screening.
Rheumatoid arthritis (RA) disease control appears to be better with continued 4-mg baricitinib treatment than with a 2-mg dose step-down approach, according to substudy data from the ongoing phase III RA-BEYOND extension trial.
Initiation of abatacept (ABA) vs tumour necrosis factor inhibitors (TNFi) leads to a 20-percent reduction in risk of cardiovascular disease (CVD) in a large cohort of insured patients with rheumatoid arthritis (RA), a US study has shown.
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.